Saturday, September 12, 2026

CT-P72/ABP-102: The Next Big Breakthrough in HER2 Cancer Treatment?

Celltrion's CT-P72/ABP-102 shows strong efficacy against HER2 tumors, promising for treating various cancers with reduced toxicity.

CHA Biotech Partners With Thermo Fisher to Build K-Bio Open Innovation Hub in Pangyo

Cha Biotech partners with Thermo Fisher to establish K-Bio CIC, enhancing biotech innovation and global market entry support.

North Korea Humanitarian Aid: What the Latest Sanctions Waiver Means for 2026

The Blue House supports U.S. exemptions for humanitarian aid to North Korea, emphasizing consistent aid regardless of political tensions.

Tag: ALT-B4

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Alteogen Signs Subcutaneous Injection Development Deal With Novartis Worth Up to $3.22 Billion

Alteogen has signed an option and licensing agreement with Novartis to develop and commercialize subcutaneous formulations based on its ALT-B4 technology, with potential payments of up to $3.22 billion plus royalties.

Alteogen and Biogen: A Game-Changing 200 Million USD License Deal for ALT-B4 Biopharmaceuticals

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

Alteogen Secures U.S. Patent for Keytruda Subcutaneous Injection: What This Means for ALT-B4 and Future Treatments

Alteogen secures a U.S. patent for a subcutaneous Keytruda formulation using ALT-B4, ensuring exclusivity until 2043 and potential $1B in sales.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.